IP Library › Granted Patent US 12,163,967
Granted Patent B2
US 12,163,967 · App. 16/945,960 · Granted Dec 10, 2024

Blood analysis systems and methods

Inventors: Frederic Buffiere (Marnes la Coquette, FR); Sylvie Villard-Saussine (Marnes la Coquette, FR); Eliane Rivalin (Marnes la Coquette, FR); Laurent Guillon (Marnes la Coquette, FR); Johann Guegan (Marnes la Coquette, FR)
Assignee: BIO-RAD EUROPE GMBH
G01N33/80B01L3/502761B01L3/502776B01L3/5085G01N33/54306G01N33/54373G01N33/56966B01L3/502715B01L3/502753B01L2200/0652B01L2300/024B01L2300/027B01L2300/0636B01L2300/0822B01L2300/0829B01L2300/0864B01L2300/0883B01L2300/089B01L2300/0896B01L2300/163B01L2400/0406
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,163,967
App. No.
16/945,960
Granted
Dec 10, 2024
Kind
B2
Abstract

Blood typing systems and methods are provided. In one embodiment, the method may be achieved by applying a sample to a surface of a substrate having one or more binding agents immobilized thereon, wherein the one or more binding agents are capable of binding to one or more substances in the sample; substantially removing unbound material from at least a portion of the substrate having immobilized binding agent; and detecting substances bound to the one or more binding agents immobilized on the substrate; wherein the applying the sample to the surface of the substrate step is concurrent with the removing unbound material from at least a portion of the substrate step. Systems and other methods are also described and illustrated.

Claims (14)

1. A blood analysis system comprising:

a substrate having a binding agent immobilized in discreet locations, wherein the binding agent comprises one or more antibodies that bind to: antigens at the surface of red blood cells, antigens on one or more native or hemolyzed phenotyped red blood cells, one or more recombinant blood group antigens, or one or more antibodies to red blood cell antigens;

a dispenser comprising a plurality of microchannels configured to simultaneously dispense a sample comprising the antigen to which the binding agent binds onto the substrate and to remove the sample from the substrate, the plurality of microchannels comprising microchannels that exclude red blood cells based on size and microchannels sized to allow red blood cells from the sample to flow therethrough;

a light source configured to illuminate the substrate; and

a detector configured to detect the presence or absence of red blood cell components bound to the binding agent.

2. The blood analysis system of claim 1 , wherein the microchannels that exclude red blood cells have a cross section having a diameter of less than 6 micrometers.

3. The blood analysis of claim 2 , wherein the microchannels that exclude red blood cells have a cross section having a diameter of less than 6 micrometers and the microchannels sized to allow red blood cells from a sample to flow therethrough have a diameter of at least 7 micrometers.

4. A blood analysis system for cross-matching comprising:

a substrate having donor red blood cells immobilized in discreet locations thereon;

a dispenser configured to simultaneously dispense donor red blood cells or patient plasma onto the substrate and to remove unbound donor red blood cells or unbound components of the patient plasma from the substrate, the dispenser comprising a microfluidic probe having microchannels that exclude red blood cells based on size and microchannels sized to allow red blood cells from a sample to flow therethrough;

a light source configured to illuminate the substrate; and

a detector configured to detect the presence or absence of antibodies bound to the donor red blood cells.

5. The blood analysis system of claim 4 , wherein the microchannels that exclude red blood cells have a cross section having a diameter of less than 6 micrometers.

6. The blood analysis system of claim 5 , wherein the microchannels that exclude red blood cells have a cross section having a diameter of less than 6 micrometers and the microchannels sized to allow red blood cells from a sample to flow therethrough have a diameter of at least 7 micrometers.

Priority Claims (1)
EP 15151176 · Jan 14, 2015 · regional
Continuity (2)
Division 15543579
Related Publication 20200363434A1 · Nov 19, 2020